K. Clinton Cary, MD, MPH
Assistant Professor, Department of Urology, Indiana University School of Medicine
Research Scientist, Indiana University Center for Health Services and Outcomes Research
Research Scientist, William M. Tierney Center for Health Services Research, Regenstrief Institute, Inc.
Dr. Cary is a research scientist in Regenstrief Institute's William M. Tierney Center for Health Services Research and Assistant Professor in the Department of Urology at Indiana University School of Medicine. Dr. Cary provides direct medical and surgical care for general urology and urologic oncology patients. His research efforts are focused on improving the health of patients with urologic cancers through health services and outcomes research in testis, bladder, and prostate cancer. He has an active pilot study in progress to assess utilization rates of single dose intravesical chemotherapy in patients with non-muscle invasive bladder cancer in a population-based environment.
Dr. Cary serves on the Scientific Review Committee at the Indiana University Simon Cancer Center, the Medical Staff Oversight and Credentials Committees at Eskenazi Health, and the Cancer Registry Advisory Board at the Indiana State Department of Health.
Dr. Cary is licensed by the Medical Licensing Board of the State of Indiana and a staff physician at Indiana University Health.
|Urologic Oncology, including:|
|Robotic Surgery in Urologic Cancers|
HOSPITALS & AFFILIATIONS
|IU Health Physicians|
|IU Health Methodist/IU Health University|
|Masters Degree|| University of California Berkeley
|School of Medicine||University of Tennessee Health Science Center|
|Internship|| Indiana University
|Fellowship||University of California, San Francisco|
I. Regenstrief Institute, Inc. (2015)
“Assessing Utilization of Intravesical Chemotherapy in Bladder Cancer (PI)
Pilot study to identify rates of utilization among physicians of single dose intravesical chemotherapy, an evidence-based treatment following transurethral tumor resection to reduce tumor recurrence and potentially ease the economic burden of cancer surveillance.
II. IU Simon Cancer Center (2014-2016)
"Genomic Markers in Transitional Cell Cancer of the Bladder, Renal Pelvis and Ureter: Sample Acquisition for Methods Development and Discovery". Genomic Health. (PI)
|Selected Publications|||||Go To PubMed List >>|
1. Pedrosa JA, Koch MO, Kaimakliotis HZ, Monn MF, Masterson TA, Rice KR, Cary KC, Foster RS, Bihrle R, Cheng L. Three-tiered nodal classification system for bladder cancer: a new proposal. Future Oncology. 2015;11(3):399-408.
2. Cary C, Masterson TA, Bihrle R, Foster RS. Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: Additional procedures and perioperative complications. Urologic Oncology. 2015 Jan 5. pii: S1078-1439(14)00270-1.
3. Monn MF, Kaimakliotis HZ, Pedrosa JA, Cary KC, Bihrle R, Cheng L, Koch MO. Contemporary bladder cancer: variant histology may be a significant driver of disease. Urologic Oncology. 2015 Jan;33(1):18.e15-20.
4. Cary KC, Pedrosa JA, Kaimakliotis HZ, Masterson TA, Einhorn LH, Foster RS. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors. The Journal of Urology. 2015 Feb;193(2):507-12.
5. Yang DY, Monn MF, Kaimakliotis HZ, Cary KC, Cheng L, Koch MO. Oncologic and quality-of-life outcomes with wide resection in robot-assisted laparoscopic radical prostatectomy. Urologic Oncology. 2015 Feb;33(2):70.e9-14.
6. Monn MF, Kaimakliotis HZ, Cary KC, Bihrle R, Pedrosa JA, Masterson TA, Foster RS, Gardner TA, Cheng L, Koch MO. The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity? BJU International. 2014 Jul 25 [Epub ahead of print]
7. Pedrosa JA, Kaimakliotis HZ, Monn MF, Cary KC, Masterson TA, Rice KR, Foster RS, Bihrle R, Koch MO, Cheng L. Critical analysis of the 2010 TNM classification in patients with lymph node-positive bladder cancer: influence of lymph node disease burden. Urologic Oncology. 2014 Oct;32(7):1003-9.
8. Kaimakliotis HZ, Monn MF, Cary KC, Pedrosa JA, Rice K, Masterson TA, Gardner TA, Hahn NM, Foster RS, Bihrle R, Cheng L, Koch MO. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? Urologic Oncology. 2014 Aug;32(6):833-8.
9. Rice KR, Magers MJ, Beck SD, Cary KC, Einhorn LH, Ulbright TM, Foster RS. Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes. The Journal of Urology. 2014 Nov;192(5):1403-9.
10. Monn MF, Cary KC, Kaimakliotis HZ, Flack CK, Koch MO. National trends in the utilization of robotic-assisted radical cystectomy: an analysis using the Nationwide Inpatient Sample. Urologic Oncology. 2014 Aug;32(6):785-90.
11. Monn MF, Kaimakliotis HZ, Cary KC, Pedrosa JA, Flack CK, Koch MO, Bihrle R. Short-term morbidity and mortality of Indiana pouch, ileal conduit, and neobladder urinary diversion following radical cystectomy. Urologic Oncology. 2014 Nov;32(8):1151-7.
12. Rice KR, Beck SD, Bihrle R, Cary KC, Einhorn LH, Foster RS. Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection. The Journal of Urology. 2014 Nov;192(5):1397-402.
13. Wang SY, Cowan JE, Cary KC, Chan JM, Carroll PR, Cooperberg MR. Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU International. 2014 Dec;114(6b):E18-24.
14. Kaimakliotis HZ, Monn MF, Cheng L, Masterson TA, Cary KC, Pedrosa JA, Foster RS, Koch MO, Bihrle R. Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology. 2014 May;83(5):1112-6.
15. Cary KC, Paciorek A, Fuldeore MJ, Carroll PR, Cooperberg MR. Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry. Cancer. 2014 Feb 15;120(4):507-12.
16. Cary KC, Singla N, Cowan JE, Carroll PR, Cooperberg MR. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE™ registry. The Journal of Urology. 2014 Apr;191(4):964-70.
17. Cary KC, Cowan JE, Sanford M, Shinohara K, Perez N, Chan JM, Meng MV, Carroll PR. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. European Urology. 2014 Aug;66(2):337-42.